Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPTSY Biophytis	$2.00	$1.65	$1.33 ▼ $7.48	$702K	0.85	1,678 shs	2 shs
GLMD Galmed Pharmaceuticals	$1.43 -4.4%	$1.75	$1.15 ▼ $23.80	$2.36M	0.58	1.06 million shs	635,049 shs
LIPO Lipella Pharmaceuticals	$0.59 +0.5%	$0.89	$0.55 ▼ $7.31	$2.74M	-0.1	874,109 shs	5,105 shs
SPRC SciSparc	$4.26 -8.0%	$6.30	$4.00 ▼ $37.59	$2.26M	0.88	161,325 shs	116,263 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPTSY Biophytis	0.00%	0.00%	+10.80%	+15.61%	-69.97%
GLMD Galmed Pharmaceuticals	0.00%	+3.47%	-25.13%	+7.19%	-58.65%
LIPO Lipella Pharmaceuticals	0.00%	-6.32%	-5.87%	-79.65%	-85.80%
SPRC SciSparc	0.00%	+2.66%	-36.31%	-28.30%	-39.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPTSY Biophytis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	1.0629 of 5 stars	0.0	5.0	0.0	0.0	0.0	2.5	0.6
LIPO Lipella Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SPRC SciSparc	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPTSY Biophytis	0.00	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	2.00	Hold	N/A	N/A
LIPO Lipella Pharmaceuticals	0.00	N/A	N/A	N/A
SPRC SciSparc	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPTSY Biophytis	N/A	N/A	N/A	N/A	($16.18) per share	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$9.87 per share	N/A
LIPO Lipella Pharmaceuticals	$536.36K	5.11	N/A	N/A	$1.59 per share	0.37
SPRC SciSparc	$1.31M	1.72	N/A	N/A	$18.13 per share	0.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPTSY Biophytis	-$18.43M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	-$7.52M	-$16.66	N/A	∞	N/A	N/A	-32.21%	-28.59%	8/27/2025 (Estimated)
LIPO Lipella Pharmaceuticals	-$5.02M	-$3.43	N/A	∞	N/A	-988.83%	-224.08%	-172.88%	N/A
SPRC SciSparc	-$6.28M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPTSY Biophytis	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SPRC SciSparc	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPTSY Biophytis	N/A	0.41	N/A
GLMD Galmed Pharmaceuticals	N/A	9.02	9.02
LIPO Lipella Pharmaceuticals	N/A	6.21	6.21
SPRC SciSparc	N/A	5.36	5.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPTSY Biophytis	0.05%
GLMD Galmed Pharmaceuticals	76.14%
LIPO Lipella Pharmaceuticals	74.31%
SPRC SciSparc	25.06%

Insider Ownership

Company	Insider Ownership
BPTSY Biophytis	3.70%
GLMD Galmed Pharmaceuticals	19.80%
LIPO Lipella Pharmaceuticals	32.11%
SPRC SciSparc	1.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPTSY Biophytis	30	351,000	338,000	N/A
GLMD Galmed Pharmaceuticals	20	1.65 million	1.33 million	Not Optionable
LIPO Lipella Pharmaceuticals	4	4.62 million	3.03 million	Not Optionable
SPRC SciSparc	4	530,000	527,000	Not Optionable

BPTSY, LIPO, SPRC, and GLMD Headlines

Recent News About These Companies

SciSparc Announces Patent Filing and Merger Updates

August 8, 2025 | theglobeandmail.com

SciSparc and Clearmind Publish Patent for Novel Obesity Therapy

August 8, 2025 | tipranks.com

SciSparc Ltd. and Clearmind Medicine Inc. Collaborate to Launch International Patent Application for Innovative Therapy Targeting Metabolic Syndrome and Obesity

August 7, 2025 | quiverquant.comQ

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

August 7, 2025 | globenewswire.com

SciSparc Ltd: SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

July 31, 2025 | finanznachrichten.de

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

July 30, 2025 | globenewswire.com

Clearmind Medicine files international patent application under PCT

July 30, 2025 | msn.com

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

July 30, 2025 | globenewswire.com

SciSparc Ltd. Regains Nasdaq Compliance

July 22, 2025 | tipranks.com

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

July 22, 2025 | globenewswire.com

SciSparc Announces 1-for-21 Reverse Share Split - Morningstar

June 26, 2025 | morningstar.comM

SciSparc Ltd. Adjourns Annual Meeting Due to Lack of Quorum

June 25, 2025 | msn.com

SciSparc Ltd: SciSparc Announces 1-for-21 Reverse Share Split

June 25, 2025 | finanznachrichten.de

SciSparc Ltd. Announces One-for-Twenty One Reverse Share Split Effective July 3, 2025

June 24, 2025 | quiverquant.comQ

SciSparc Announces 1-for-21 Reverse Share Split

June 24, 2025 | globenewswire.com

SciSparc secures Japanese patent for pain relief combo

May 28, 2025 | investing.com

SciSparc Unveils Japanese Patent for Novel Pain Relief Combination

May 27, 2025 | tipranks.com

SciSparc Ltd. Announces Publication of Novel Japanese Patent for Enhanced Pain Management Therapy Combining Paracetamol and PEA

May 27, 2025 | quiverquant.comQ

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025 | globenewswire.com

SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc.

May 13, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY, LIPO, SPRC, and GLMD Company Descriptions

Biophytis NASDAQ:BPTSY

$2.00 0.00 (0.00%)

As of 08/22/2025

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Galmed Pharmaceuticals NASDAQ:GLMD

$1.42 -0.07 (-4.36%)

As of 03:46 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Lipella Pharmaceuticals NASDAQ:LIPO

$0.59 +0.00 (+0.51%)

As of 11:47 AM Eastern

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

SciSparc NASDAQ:SPRC

$4.26 -0.37 (-7.99%)

As of 03:48 PM Eastern

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time